Sugi Predict

Sugi Predict / Compounds / SCHEMBL15520797

SCHEMBL15520797

SCHEMBL15520797

N#Cc1ccc(Cn2cc(N)cn2)cc1

nearest known ligand 0.62

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.62
▸ LMNA P02545 1/20 0.62
▸ CYP19A1 P11511 12/20 0.54
▸ KLKB1 P03952 1/20 0.51
▸ MEN1 O00255 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.45
▸ PKM P14618 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ CYP11B1 P15538 4/20 0.44
▸ CYP11B2 P19099 4/20 0.44
▸ ITK Q08881 1/20 0.44
▸ LOXL2 Q9Y4K0 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14699090 0.82 MEN1 (0.59) MAPTLMNACYP19A1KLKB1MEN1
Hydrochloric Acid SCHEMBL21492793 0.81 LOXL2 (0.53) MAPTLMNACYP19A1KLKB1CYP11B1
SCHEMBL19087155 0.81 CYP19A1 (0.54) CYP19A1KLKB1CYP11B1CYP11B2
SCHEMBL28419208 0.81 CYP19A1 (0.54) CYP19A1CYP11B1CYP11B2ITK
SCHEMBL712713 0.80 MAPT (0.70) MAPTLMNAKLKB1MEN1KMT2A
SCHEMBL30730357 0.79 HSD17B10 (0.57) CYP19A1KLKB1ALDH1A1L3MBTL1CYP11B1
SCHEMBL30739125 0.79 KLKB1 (0.53) LMNACYP19A1KLKB1ALDH1A1CYP11B1
SCHEMBL19077891 0.78 CYP19A1 (0.51) CYP19A1KLKB1CYP11B1CYP11B2ITK
Hydrochloric Acid SCHEMBL712415 0.78 MAPT (0.73) MAPTLMNAKLKB1MEN1KMT2A
SCHEMBL3593783 0.78 MAPT (0.68) MAPTLMNAKLKB1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12325702-B2 ATF6 inhibitors and uses thereof ALTOS LABS, INC. (US) 2025-06-10 — — US disclosed
CN-119060036-A ATF6 inhibitors and uses thereof 阿尔托斯实验室公司 2024-12-03 — — CN disclosed
CN-112313224-B ATF6 inhibitors and uses thereof 阿尔托斯实验室公司 2024-08-13 — — CN disclosed
US-20240124434-A1 ATF6 INHIBITORS AND USES THEREOF ALTOS LABS, INC. 2024-04-18 — — US disclosed
US-20210221803-A1 ATF6 INHIBITORS AND USES THEREOF ALTOS LABS, INC. 2021-07-22 — — US disclosed
US-20210221803-A1 ATF6 INHIBITORS AND USES THEREOF ALTOS LABS, INC. 2021-07-22 — — US disclosed
CN-112313224-A ATF6 inhibitors and uses thereof 黑带医疗有限责任公司 2021-02-02 — — CN disclosed
US-20200361905-A1 Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity VERNALIS R&D LTD (GB) 2020-11-19 — — US disclosed
US-10829485-B2 ATF6 inhibitors and uses thereof BLACK BELT TX LTD (GB) 2020-11-10 — — US disclosed
US-10829485-B2 ATF6 inhibitors and uses thereof BLACK BELT TX LTD (GB) 2020-11-10 — — US disclosed
US-10696652-B2 Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity VERNALIS (R&D) LTD. (GB) 2020-06-30 — — US disclosed
US-20180244652-A1 Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity VERNALIS (R&D) LTD. (GB) 2018-08-30 — — US disclosed
US-20170298043-A1 Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity VERNALIS (R&D) LTD. (GB) 2017-10-19 — — US disclosed
US-9604975-B2 Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity VERNALIS (R&D) LTD (GB) 2017-03-28 — — US disclosed
US-20150099736-A1 Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity VERNALIS (R&D) LTD (GB) 2015-04-09 — — US disclosed
EP-2294065-B1 INDOLYL-PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY VERNALIS R&D LTD (GB) 2014-03-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124434-A1 ATF6 INHIBITORS AND USES THEREOF ATF4, XBP1, ATF1 MAPT 264/4885LMNA 2920/4885CYP19A1 3848/4885
US-12325702-B2 ATF6 inhibitors and uses thereof ATF4, XBP1, ATF1 MAPT 264/4885LMNA 2920/4885CYP19A1 3848/4885
US-20170298043-A1 Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity CHEK1, CHEK2, RAD1 MAPT 4198/4885LMNA 1114/4885CYP19A1 2478/4885
US-20200361905-A1 Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity CHEK2, CHEK1, BUB1B MAPT 2482/4885LMNA 2426/4885CYP19A1 3092/4885
US-10829485-B2 ATF6 inhibitors and uses thereof ATF4, XBP1, ATF1 MAPT 264/4885LMNA 2920/4885CYP19A1 3848/4885
US-20150099736-A1 Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity CHEK1, CHEK2, RAD1 MAPT 4198/4885LMNA 1114/4885CYP19A1 2478/4885
US-20210221803-A1 ATF6 INHIBITORS AND USES THEREOF ATF4, XBP1, ATF1 MAPT 264/4885LMNA 2920/4885CYP19A1 3848/4885
US-10696652-B2 Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity CHEK2, CHEK1, BUB1B MAPT 2482/4885LMNA 2426/4885CYP19A1 3092/4885
US-20180244652-A1 Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity CHEK2, CHEK1, BUB1B MAPT 2482/4885LMNA 2426/4885CYP19A1 3092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.